Genmab says choosing to insource cell-line development helped them to improve the antibody titers they were achieving.

To address this, researchers developed a "cell line atlas," which is a collection of cancer cell lines—each derived from an individual patient's tumor and adapted to grow in the lab—with ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

After Bicara reported a 12-month OS of 61% for its HPV-negative population last week, biotech Merus shared that its ...

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Impact of ...

antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated in an ongoing global Phase 1a/1b clinical trial ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by the development and regulatory ...

It is highly expressed in glioblastoma multiforme, the most aggressive brain tumor in adults, and in its stem cells [glioblastoma stem cells (GSCs)], which contribute to treatment resistance and tumor ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...